⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NKTX News
Nkarta, Inc. Common Stock
NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025
businesswire.com
NKTX
Nkarta to Participate in Evercore Healthcare Conference
globenewswire.com
NKTX
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
globenewswire.com
NKTX
Nkarta to Participate in November Investor Conferences
globenewswire.com
NKTX